Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Received kidney transplant at least 3 months prior to study enrollment~* Receiving immunosuppressive regimen that includes MMF in combination with other immunosuppressive drugs~* Receiving MMF for at least 1 month prior to enrollment~Exclusion Criteria:~* Patients with any known hypersensitivity against mycophenolic acid, mycophenolate sodium, mycophenolate mofetil or other components of the formulations (e.g. lactose; see also summary of product characteristics of EC-MPS)~* If applicable, GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea)~* Acute rejection \< 1 week prior to study enrollment~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myfortic (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).